SG10201700527UA - Composition for treating hyperlipidemia comprising oxyntomodulin derivative - Google Patents

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

Info

Publication number: SG10201700527UA
Authority: SG; Singapore
Prior art keywords: composition; treating hyperlipidemia; oxyntomodulin derivative; oxyntomodulin; derivative
Prior art date: 2012-07-25

Application number

SG10201700527UA

Other languages

English (en)

Inventor

Sung Youb Jung

Jin-Sun Kim

Myung Hyun Jang

Sang Hyun Lee

In Young Choi

Se Chang Kwon

Original Assignee

Hanmi Pharm Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-25

Filing date

2013-07-25

Publication date

2017-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49997578&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201700527U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-25 Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd

2017-02-27 Publication of SG10201700527UA publication Critical patent/SG10201700527UA/en

Links

208000031226 Hyperlipidaemia Diseases 0.000 title 1
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

SG10201700527UA 2012-07-25 2013-07-25 Composition for treating hyperlipidemia comprising oxyntomodulin derivative SG10201700527UA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR1020120081475A KR101968344B1 (ko)	2012-07-25	2012-07-25	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Publications (1)

Publication Number	Publication Date
SG10201700527UA true SG10201700527UA (en)	2017-02-27

Family

ID=49997578

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201700527UA SG10201700527UA (en)	2012-07-25	2013-07-25	Composition for treating hyperlipidemia comprising oxyntomodulin derivative
SG11201500519UA SG11201500519UA (en)	2012-07-25	2013-07-25	Composition for treating hyperlipidemia comprising oxyntomodulin derivative

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201500519UA SG11201500519UA (en)	2012-07-25	2013-07-25	Composition for treating hyperlipidemia comprising oxyntomodulin derivative

Country Status (25)

Country	Link
US (3)	US20150182593A1 (es)
EP (3)	EP3766520A1 (es)
JP (4)	JP2015524427A (es)
KR (1)	KR101968344B1 (es)
CN (2)	CN104507492B (es)
AR (1)	AR091903A1 (es)
AU (2)	AU2013293714B2 (es)
BR (2)	BR112015001596B1 (es)
CA (2)	CA2888407C (es)
CL (4)	CL2015000177A1 (es)
DK (1)	DK3384925T3 (es)
ES (2)	ES2942187T3 (es)
HK (1)	HK1206280A1 (es)
IL (2)	IL236913B (es)
MX (2)	MX360024B (es)
MY (2)	MY171493A (es)
NZ (2)	NZ731657A (es)
PE (1)	PE20150633A1 (es)
PH (2)	PH12015500158B1 (es)
RU (2)	RU2768853C1 (es)
SG (2)	SG10201700527UA (es)
TW (3)	TWI708614B (es)
UA (1)	UA118177C2 (es)
WO (1)	WO2014017843A1 (es)
ZA (2)	ZA201501238B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2838503C (en)	2011-06-10	2020-02-18	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PH12018501119A1 (en)	2011-06-17	2019-02-04	Hanmi Science Co Ltd	A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA031852B1 (ru)	2012-11-06	2019-03-29	Ханми Фарм. Ко., Лтд.	Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
BR112015014510A2 (pt)	2012-12-21	2017-11-21	Sanofi Sa	agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
AR098616A1 (es) *	2013-12-18	2016-06-01	Lilly Co Eli	Péptido para el tratamiento de hipoglicemia severa
PE20161153A1 (es)	2014-01-20	2016-10-27	Hanmi Pharm Ind Co Ltd	Insulina de accion prolongada y uso de la misma
WO2015152618A1 (ko) *	2014-03-31	2015-10-08	한미약품 주식회사	면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) *	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) *	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
PE20171154A1 (es)	2014-12-30	2017-08-16	Hanmi Pharm Ind Co Ltd	Derivados de glucagon con estabilidad mejorada
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
MX2017016845A (es)	2015-06-30	2018-08-01	Hanmi Pharm Ind Co Ltd	Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	Análogos de insulina novedosos
CN108699125B (zh) *	2015-12-31	2022-10-28	韩美药品株式会社	胰高血糖素/glp-1/gip受体三重激动剂
AR107823A1 (es)	2016-03-07	2018-06-06	Hanmi Pharm Ind Co Ltd	Derivados de polietilenglicol y uso de los mismos
SG11201806342SA (en) *	2016-03-10	2018-08-30	Medimmune Ltd	Glucagon and glp-1 co-agonists for the treatment of obesity
CN106046145B (zh) *	2016-04-22	2022-11-04	深圳市图微安创科技开发有限公司	Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
UA126662C2 (uk) *	2016-06-29	2023-01-11	Ханмі Фарм. Ко., Лтд.	Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
KR20180033105A (ko)	2016-09-23	2018-04-02	한미약품 주식회사	인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
WO2018069422A1 (en) *	2016-10-12	2018-04-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease
CN110545852B (zh)	2017-02-07	2023-05-26	韩美药品株式会社	非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
AU2018239037B2 (en)	2017-03-23	2022-05-26	Hanmi Pharm. Co., Ltd.	Insulin analog complex with reduced affinity for insulin receptor and use thereof
AU2018314773A1 (en) *	2017-08-09	2020-03-26	Sanofi	GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
HRP20240371T1 (hr) *	2017-08-16	2024-06-07	Dong-A St Co., Ltd	Peptidni analog aciliranog oksintomodulina
CN114920818B (zh) *	2017-11-06	2024-02-27	深圳市图微安创科技开发有限公司	基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
WO2019171352A2 (en) *	2018-03-08	2019-09-12	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
KR20200135618A (ko) *	2019-05-23	2020-12-03	㈜ 디앤디파마텍	폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
WO2020017919A1 (ko) *	2018-07-19	2020-01-23	한미정밀화학주식회사	생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
BR112021000933A2 (pt) *	2018-07-19	2021-04-27	D&D Pharmatech Inc.	polipeptídeo, composição farmacêutica, método de preparação dela e método de prevenção ou tratamento de doenças
US20200262887A1 (en)	2018-11-30	2020-08-20	Opko Ireland Global Holdings, Ltd.	Oxyntomodulin peptide analog formulations
WO2020128967A2 (en) *	2018-12-19	2020-06-25	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
WO2020167010A1 (ko) *	2019-02-15	2020-08-20	한미정밀화학주식회사	생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
GB202001024D0 (en) *	2020-01-24	2020-03-11	Key Bioscience Ag	Oxyntomodulin mimetics

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
AU749815B2 (en)	1998-03-06	2002-07-04	Chugai Seiyaku Kabushiki Kaisha	Protein-free preparations
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
US7217845B2 (en)	2002-11-25	2007-05-15	Sun Bio, Inc.	Bifunctional polyethylene glycol derivatives
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
US7772188B2 (en) *	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en)	2003-10-16	2005-04-21	Compugen Ltd.	Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US8263084B2 (en) *	2003-11-13	2012-09-11	Hanmi Science Co., Ltd	Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko)	2007-11-29	2012-04-24	한미사이언스 주식회사	인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090238838A1 (en)	2003-11-13	2009-09-24	Hanmi Pharm. Ind. Co. Ltd.	Insulinotropic peptide conjugate using an immunoglobulin fc
CN103212084B (zh)	2003-11-13	2018-07-13	韩美科学株式会社	含有免疫球蛋白fc区作为载体的药物组合物
CA2589800A1 (en)	2004-12-02	2006-06-08	Domantis Limited	Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
US8404637B2 (en)	2005-02-11	2013-03-26	Amylin Pharmaceuticals, Llc	GIP analog and hybrid polypeptides with selectable properties
KR100754667B1 (ko)	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en)	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
WO2006134340A2 (en) *	2005-06-13	2006-12-21	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
EP2330124B1 (en)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
CA2638800A1 (en) *	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
EP2046367A4 (en)	2006-06-07	2009-11-11	Human Genome Sciences Inc	ALBUM INFUSION PROTEINS
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
GB0624868D0 (en)	2006-12-13	2007-01-24	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en)	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
KR20150116465A (ko)	2007-02-15	2015-10-15	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/ｇｌｐ-1 수용체 공동-항진물질
EA201070121A1 (ru)	2007-07-10	2010-06-30	Эли Лилли Энд Компани	Лекарственная форма, содержащая слитый белок glp-1-fc
KR20100061679A (ko) *	2007-09-11	2010-06-08	몬도바이오테크 래보래토리즈 아게	치료적 적용을 위한 티로트로핀 방출 호르몬
CA2702289A1 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009099763A1 (en)	2008-01-30	2009-08-13	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
JP5753779B2 (ja)	2008-06-17	2015-07-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
NZ589847A (en)	2008-06-17	2013-01-25	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
WO2010013012A2 (en)	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
US20110171312A1 (en)	2008-09-19	2011-07-14	Nektar Therapeutics	Modified therapeutic peptides, methods of their preparation and use
WO2010033207A1 (en)	2008-09-19	2010-03-25	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
JP5635531B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
WO2010070255A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
AR074811A1 (es)	2008-12-19	2011-02-16	Univ Indiana Res & Tech Corp	Profarmaco de peptido de la superfamilia de glucagon basados en amida
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
EP2408800B1 (en)	2009-03-20	2016-05-25	Hanmi Science Co., Ltd.	Method for preparing a site-specific conjugate of a physiologically active polypeptide
EP3385279B1 (en)	2009-03-20	2020-02-26	Amgen Inc.	Carrier immunoglobulins and uses thereof
KR20120087875A (ko)	2009-06-16	2012-08-07	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	Ｇｉｐ 수용체-활성 글루카곤 화합물
ME02220B (me)	2009-07-13	2016-02-20	Zealand Pharma As	Analozi acilovanog glukagona
US20120294855A1 (en)	2009-11-03	2012-11-22	Eli Lilly & Company	Glp-1 receptor agonist compounds for obstructive sleep apnea
EP2509997B1 (en) *	2009-12-07	2017-08-30	i2 Pharmaceuticals, Inc.	Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
EP2512503A4 (en) *	2009-12-18	2013-08-21	Univ Indiana Res & Tech Corp	COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
US20130143798A1 (en)	2010-03-26	2013-06-06	Novo Nordisk A/S	Novel glucagon analogues
CA2797089A1 (en) *	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2011163012A2 (en)	2010-06-24	2011-12-29	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
KR101382593B1 (ko)	2010-07-21	2014-04-10	한미사이언스 주식회사	신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) *	2010-09-15	2011-02-16	南京瑞年天平医药科技有限公司	一种新颖的多肽化合物
KR101303388B1 (ko)	2010-10-26	2013-09-03	한미사이언스 주식회사	지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) *	2010-10-26	2017-08-14	한미사이언스 주식회사	항 비만 펩타이드의 지속형 결합체
CN102010473A (zh)	2010-11-10	2011-04-13	曹鹏	重组胃泌酸调节素融合蛋白及其制备和应用
US8975223B2 (en)	2010-12-22	2015-03-10	Marcadia Biotech, Inc.	Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
JP6118500B2 (ja)	2011-02-28	2017-04-19	ロームアンドハースエレクトロニックマテリアルズエルエルシーＲｏｈｍａｎｄＨａａｓＥｌｅｃｔｒｏｎｉｃＭａｔｅｒｉａｌｓＬＬＣ	フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko)	2011-05-16	2012-07-02	숭실대학교산학협력단	연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
CA2838503C (en)	2011-06-10	2020-02-18	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PH12018501119A1 (en) *	2011-06-17	2019-02-04	Hanmi Science Co Ltd	A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
RU2014101697A (ru)	2011-06-22	2015-07-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Коагонисты рецепторов глюкагона/glp-1
KR101665009B1 (ko)	2012-03-09	2016-10-11	한미사이언스 주식회사	비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
SG11201406671RA (en)	2012-04-19	2014-11-27	Opko Biolog Ltd	Long-acting oxyntomodulin variants and methods of producing same
EP2864351B1 (en)	2012-06-21	2016-08-10	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA031852B1 (ru) *	2012-11-06	2019-03-29	Ханми Фарм. Ко., Лтд.	Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
JP6137046B2 (ja)	2014-05-09	2017-05-31	信越化学工業株式会社	単量体、高分子化合物、レジスト材料及びパターン形成方法

2012
- 2012-07-25 KR KR1020120081475A patent/KR101968344B1/ko active IP Right Grant
2013
- 2013-07-24 AR ARP130102654A patent/AR091903A1/es not_active Application Discontinuation
- 2013-07-25 MY MYPI2015000190A patent/MY171493A/en unknown
- 2013-07-25 SG SG10201700527UA patent/SG10201700527UA/en unknown
- 2013-07-25 AU AU2013293714A patent/AU2013293714B2/en active Active
- 2013-07-25 WO PCT/KR2013/006668 patent/WO2014017843A1/en active Application Filing
- 2013-07-25 BR BR112015001596-4A patent/BR112015001596B1/pt active IP Right Grant
- 2013-07-25 SG SG11201500519UA patent/SG11201500519UA/en unknown
- 2013-07-25 PE PE2015000094A patent/PE20150633A1/es not_active Application Discontinuation
- 2013-07-25 CA CA2888407A patent/CA2888407C/en active Active
- 2013-07-25 TW TW106127084A patent/TWI708614B/zh active
- 2013-07-25 UA UAA201501078A patent/UA118177C2/uk unknown
- 2013-07-25 NZ NZ731657A patent/NZ731657A/en unknown
- 2013-07-25 ES ES13823727T patent/ES2942187T3/es active Active
- 2013-07-25 EP EP20188520.9A patent/EP3766520A1/en active Pending
- 2013-07-25 EP EP13823727.6A patent/EP2884994B1/en active Active
- 2013-07-25 TW TW109133876A patent/TWI780493B/zh active
- 2013-07-25 RU RU2017143004A patent/RU2768853C1/ru active
- 2013-07-25 CN CN201380039596.XA patent/CN104507492B/zh active Active
- 2013-07-25 CN CN201710990018.4A patent/CN107854691B/zh active Active
- 2013-07-25 TW TW102126623A patent/TWI661837B/zh active
- 2013-07-25 NZ NZ705384A patent/NZ705384A/en unknown
- 2013-07-25 DK DK18169490.2T patent/DK3384925T3/da active
- 2013-07-25 BR BR122022025353-9A patent/BR122022025353B1/pt active IP Right Grant
- 2013-07-25 EP EP18169490.2A patent/EP3384925B1/en active Active
- 2013-07-25 RU RU2015104492A patent/RU2642267C2/ru active
- 2013-07-25 JP JP2015524182A patent/JP2015524427A/ja active Pending
- 2013-07-25 US US14/415,200 patent/US20150182593A1/en not_active Abandoned
- 2013-07-25 MX MX2015001218A patent/MX360024B/es active IP Right Grant
- 2013-07-25 ES ES18169490T patent/ES2842881T3/es active Active
- 2013-07-25 CA CA3121985A patent/CA3121985A1/en active Pending
2015
- 2015-01-23 PH PH12015500158A patent/PH12015500158B1/en unknown
- 2015-01-23 CL CL2015000177A patent/CL2015000177A1/es unknown
- 2015-01-25 IL IL236913A patent/IL236913B/en active IP Right Grant
- 2015-01-26 MX MX2018012686A patent/MX2018012686A/es unknown
- 2015-02-24 ZA ZA2015/01238A patent/ZA201501238B/en unknown
- 2015-07-24 HK HK15107083.6A patent/HK1206280A1/xx unknown
2016
- 2016-03-31 US US15/086,499 patent/US9901621B2/en active Active
2017
- 2017-09-27 CL CL2017002432A patent/CL2017002432A1/es unknown
- 2017-12-19 US US15/846,395 patent/US10493132B2/en active Active
2018
- 2018-01-19 JP JP2018007302A patent/JP6499333B2/ja active Active
- 2018-05-28 AU AU2018203729A patent/AU2018203729B2/en active Active
- 2018-12-24 MY MYPI2018002701A patent/MY187988A/en unknown
2019
- 2019-03-14 JP JP2019046854A patent/JP6903086B2/ja active Active
- 2019-04-23 CL CL2019001115A patent/CL2019001115A1/es unknown
- 2019-05-21 PH PH12019501131A patent/PH12019501131A1/en unknown
- 2019-08-13 ZA ZA2019/05331A patent/ZA201905331B/en unknown
2020
- 2020-04-21 IL IL274106A patent/IL274106B2/en unknown
- 2020-09-01 CL CL2020002262A patent/CL2020002262A1/es unknown
2021
- 2021-04-02 JP JP2021063405A patent/JP2021107403A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP3384925A1 (en)	2018-10-10
HK1206280A1 (en)	2016-01-08
ES2942187T3 (es)	2023-05-30
MX2015001218A (es)	2015-09-07
TWI708614B (zh)	2020-11-01
JP2021107403A (ja)	2021-07-29
US10493132B2 (en)	2019-12-03
JP2015524427A (ja)	2015-08-24
NZ705384A (en)	2018-01-26
US20180177850A1 (en)	2018-06-28
JP2019108394A (ja)	2019-07-04
EP2884994A4 (en)	2016-07-20
TW201740980A (zh)	2017-12-01
PH12019501131A1 (en)	2020-09-14
CN104507492B (zh)	2017-11-24
TWI780493B (zh)	2022-10-11
KR20140018462A (ko)	2014-02-13
EP2884994B1 (en)	2023-01-18
EP2884994A1 (en)	2015-06-24
IL274106B2 (en)	2023-08-01
JP2018090595A (ja)	2018-06-14
CN107854691B (zh)	2021-04-09
CL2017002432A1 (es)	2018-04-02
TWI661837B (zh)	2019-06-11
AU2018203729B2 (en)	2020-05-28
CL2015000177A1 (es)	2015-05-04
US20150182593A1 (en)	2015-07-02
RU2768853C1 (ru)	2022-03-25
BR122022025353B1 (pt)	2023-11-21
PH12015500158A1 (en)	2015-03-16
JP6499333B2 (ja)	2019-04-10
MX2018012686A (es)	2020-09-02
IL236913A0 (en)	2015-03-31
EP3766520A1 (en)	2021-01-20
MX360024B (es)	2018-10-18
BR112015001596B1 (pt)	2023-05-02
IL274106B1 (en)	2023-04-01
RU2015104492A (ru)	2016-09-10
CA2888407A1 (en)	2014-01-30
KR101968344B1 (ko)	2019-04-12
ZA201501238B (en)	2019-12-18
WO2014017843A1 (en)	2014-01-30
PH12015500158B1 (en)	2015-03-16
AR091903A1 (es)	2015-03-11
TW201416087A (zh)	2014-05-01
TW202106338A (zh)	2021-02-16
MY187988A (en)	2021-11-06
MY171493A (en)	2019-10-15
AU2013293714A1 (en)	2015-03-12
US20160199451A1 (en)	2016-07-14
CL2019001115A1 (es)	2019-06-28
US9901621B2 (en)	2018-02-27
AU2013293714B2 (en)	2018-03-01
EP3384925B1 (en)	2020-09-02
DK3384925T3 (da)	2020-12-07
PE20150633A1 (es)	2015-05-06
CN104507492A (zh)	2015-04-08
IL236913B (en)	2020-05-31
CL2020002262A1 (es)	2020-11-20
ZA201905331B (en)	2020-05-27
UA118177C2 (uk)	2018-12-10
BR112015001596A2 (pt)	2017-08-01
NZ731657A (en)	2020-01-31
SG11201500519UA (en)	2015-02-27
IL274106A (en)	2020-06-30
CN107854691A (zh)	2018-03-30
RU2642267C2 (ru)	2018-01-24
AU2018203729A1 (en)	2018-06-21
CA2888407C (en)	2021-08-03
CA3121985A1 (en)	2014-01-30
ES2842881T3 (es)	2021-07-15
JP6903086B2 (ja)	2021-07-14

Publication	Publication Date	Title
IL274106B1 (en)	2023-04-01	The composition containing an oxyntomodulin derivative for the treatment of hyperlipidemia
IL234989B (en)	2018-04-30	Compounds and preparations containing them for the treatment of cancer
GB2535435B (en)	2016-12-07	Methods for treating lignocellulosic materials
PL2916860T3 (pl)	2020-11-02	Kompozycja do leczenia cukrzycy zawierająca analog oksyntomoduliny
EP2902020A4 (en)	2016-03-23	COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS
IL253421B (en)	2018-07-31	Compounds for the treatment of fibrosis (Leifat)
IL250725A0 (en)	2017-04-30	Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
IL237483A0 (en)	2015-04-30	Preparations for the treatment of psoriasis
EP2558103A4 (en)	2013-09-25	PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
EP2774917A4 (en)	2015-05-06	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
SG11201500211PA (en)	2015-03-30	Composition for preventing or treating osteoarthritis
GB201010359D0 (en)	2010-08-04	Compounds for treating proliferative disorders
EP2823825A4 (en)	2015-10-14	PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
ZA201503005B (en)	2017-08-30	Ingenol-derived compounds useful for treating cancer
PL2809760T3 (pl)	2019-09-30	Sposób zmniejszania przykrych zapachów
EP2926817A4 (en)	2016-05-18	STABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS
SI2617412T1 (sl)	2016-04-29	Sestavek za topično zdravljenje
PL2663318T3 (pl)	2015-08-31	Kompozycja farmaceutyczna do leczenia raka
EP2785343A4 (en)	2015-04-15	PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
HK1203406A1 (en)	2015-10-30	New compositions for treating amyotrophic lateral sclerosis
SG11201505178VA (en)	2015-08-28	Composition for nasal application
PL2819664T3 (pl)	2017-12-29	Nowe kompozycje do leczenia stwardnienia zanikowego bocznego
HK1213809A1 (zh)	2016-07-15	用於治療肥胖症的藥物組合物
GB201009495D0 (en)	2010-07-21	Compounds for treating proliferative disorders
IL213610A0 (en)	2011-07-31	Composition for treating dermatological conditions